Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics.
About this Blog
BioWorld Perspectives is the official blog for news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs.
Subscribe to our Blog
Recent Posts
- Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally
- Where’s Superman When He’s Needed?
- Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs
- Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985
- ‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’
Categories
- Accelerated approval (2)
- acquisition (1)
- acute kidney injury (1)
- aging (1)
- AIDS (1)
- antibiotics (2)
- Antibody (2)
- Autism (1)
- Big pharma (28)
- bioethics (4)
- Biologic (8)
- Biosimilar (10)
- Biotech conferences (9)
- Biotechnology (95)
- Biotechnology Industry Organization (8)
- BLA (3)
- Cancer (16)
- Cardiovascular (2)
- China (4)
- chronic fatigue syndrome (3)
- Clinic (4)
- Clinical Trial (14)
- Collaboration (5)
- Complete Response Letter (4)
- Congress (2)
- Deals (6)
- Diabetes (1)
- DNA (2)
- Drug Approval (13)
- drug importation (1)
- embryonic stem cell research (1)
- emerging markets (2)
- epilepsy (1)
- ethics (1)
- European Medicines Agency (5)
- evolution (1)
- executive salaries (1)
- FDA (23)
- Financing (24)
- FOB (1)
- Follow-on biologic (2)
- FTC (1)
- Gene Therapy (5)
- generic (2)
- genetics (4)
- Genomics (7)
- Healthcare reform (4)
- HIV (1)
- immunotherapy (4)
- IND (2)
- Investigational New Drug Application (3)
- IPO (4)
- License (2)
- M&A (6)
- multidrug resistance (1)
- mutation (1)
- National Institutes of Health (1)
- NDA (3)
- neurology (3)
- neuroprostheses (1)
- neuroprosthetic (1)
- New Drug Application (7)
- Obesity (1)
- OIG (1)
- Orphan disease (7)
- pandemic (1)
- partnering (1)
- patent cliff (2)
- Patents (4)
- PDUFA (4)
- Personalized medicine (4)
- Pharmaceutical (21)
- Phase I (5)
- Phase II (4)
- Phase III (6)
- Pipeline (6)
- Preclinical (2)
- prostate cancer (1)
- Rare disease (3)
- Reimbursement (9)
- REMS (1)
- RNAi (2)
- SEC (1)
- sequestration (1)
- Series A (1)
- Shareholder value (1)
- siRNA (2)
- Stem cell (2)
- Supplemental new drug application (2)
- TB (1)
- traumatic brain injury (1)
- Tuberculosis (2)
- Type 2 Diabetes (1)
- Uncategorized (14)
- Vaccine (4)
- venture captial (7)
- Video (5)
- virus (2)
Tags
ABH
ASCO
BIO
Biotechnology Industry Organization
bioworld
BRIC
Celgene Corp
CEO
CFS
China
Clovis Oncology Inc
Cynthia Robbins Roth
Day Four
Day Three
Day Two
Dendreon Corp
DNA
EST
EU
FDA
HCV
Hemispherx Biopharma Inc
HIV
IPO
Janssen Labs
Mari Serebrov
MBA
Morgan Healthcare Conference
New York
New York Times
NIH
Nobel Prize
PDUFA
Pfizer Inc
PR
RNA
Roche
ROI
San Diego
San Francisco
Seattle Genetics Inc
SEC
UK
VC
Vivus Inc
Recommended Blogs
Recommended Organizations
Twitter Updates
Part of Thompson Media Group LLC: Thompson.com | Sheshunoff.com | ASPratt.com | BioWorld.com | CMEweb.com | Performanceweb.org | ASMIweb.com
© Copyright 2013 | BioWorld
© Copyright 2013 | BioWorld
Join the Conversation